<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="de">
	<id>http://kohlruebe.info/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=MariaKimbrell2</id>
	<title>Garten - Benutzerbeiträge [de]</title>
	<link rel="self" type="application/atom+xml" href="http://kohlruebe.info/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=MariaKimbrell2"/>
	<link rel="alternate" type="text/html" href="http://kohlruebe.info/index.php?title=Spezial:Beitr%C3%A4ge/MariaKimbrell2"/>
	<updated>2026-11-15T08:16:16Z</updated>
	<subtitle>Benutzerbeiträge</subtitle>
	<generator>MediaWiki 1.38.4</generator>
	<entry>
		<id>http://kohlruebe.info/index.php?title=JWH-210_Wikipedia&amp;diff=39989</id>
		<title>JWH-210 Wikipedia</title>
		<link rel="alternate" type="text/html" href="http://kohlruebe.info/index.php?title=JWH-210_Wikipedia&amp;diff=39989"/>
		<updated>2026-05-18T07:07:47Z</updated>

		<summary type="html">&lt;p&gt;MariaKimbrell2: Die Seite wurde neu angelegt: „4. Drugs &amp;lt;br&amp;gt;The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in humans. Drug discrimination is a well-known animal model of the subjec…“&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;4. Drugs &amp;lt;br&amp;gt;The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in humans. Drug discrimination is a well-known animal model of the subjective effects of drugs and correlates well with abuse liability (Young 2009; Horton et al. 2013). Assessment of abuse liability is based on several factors, including chemical structure, pharmacological mechanism of action, and finally, subjective and reinforcing behavioral effects (FDA, 2010; Swedberg, 2013).&amp;lt;br&amp;gt;Michael B Gat&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The current study indicates that the test compounds produce locomotor depression similar to that of Δ9-THC, and fully substitute for the discriminative stimulus effects of Δ9-THC. In summary, these 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion. Much of the in vivo JWH-210 powder testing of the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like the present study, focused on their abuse liability. There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.&amp;lt;br&amp;gt;Data availabili&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden JWH-210 powder headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available.&amp;lt;br&amp;gt;Data availability &amp;lt;br&amp;gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of the Council of Europe on medico-legal autopsies. Elegans demonstrated the ability to form all of the in-vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in-vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup, physiological conditions (age, gender JWH-210 powder and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite.&amp;lt;br&amp;gt;Data concerning the combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol is present in the blood. The victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author&lt;/div&gt;</summary>
		<author><name>MariaKimbrell2</name></author>
	</entry>
	<entry>
		<id>http://kohlruebe.info/index.php?title=Involuntary_Intoxication_Caused_By_Vaping_The_Synthetic_Cannabinoid_ADB-BUTINACA:_A_Case_Report&amp;diff=39978</id>
		<title>Involuntary Intoxication Caused By Vaping The Synthetic Cannabinoid ADB-BUTINACA: A Case Report</title>
		<link rel="alternate" type="text/html" href="http://kohlruebe.info/index.php?title=Involuntary_Intoxication_Caused_By_Vaping_The_Synthetic_Cannabinoid_ADB-BUTINACA:_A_Case_Report&amp;diff=39978"/>
		<updated>2026-05-18T07:02:24Z</updated>

		<summary type="html">&lt;p&gt;MariaKimbrell2: Die Seite wurde neu angelegt: „Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;4. Drugs &amp;lt;br&amp;gt;Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions…“&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;4. Drugs &amp;lt;br&amp;gt;Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.&amp;lt;br&amp;gt;Michael B Gat&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;4. Drugs &amp;lt;br&amp;gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&amp;lt;br&amp;gt;Michael B Gatch &amp;lt;br&amp;gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the cannabinoidsrc4f-adb.com highest dose tested (0.5 mg/kg).&amp;lt;br&amp;gt;Figure 1. &amp;lt;br&amp;gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate in a dose-dependent manner. A total of 5 mice in the JWH-081 (5 mg/kg, i.p.) treated group and 6 mice in the [https://cannabinoidsrc4f-adb.com/ cannabinoidsrc4f-adb.com] JWH-210 (5 mg/kg, i.p.) treated group showed loss of traction, of which 4 and 5 showed tremor, respectively. Memory retention was measured after the memory acquisition was tested as a probe trial.&amp;lt;br&amp;gt;About Powder JWH-2&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Figure 1. &amp;lt;br&amp;gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin&lt;/div&gt;</summary>
		<author><name>MariaKimbrell2</name></author>
	</entry>
	<entry>
		<id>http://kohlruebe.info/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&amp;diff=39975</id>
		<title>Understanding 5CLADBA: An Overview For Responsible Research</title>
		<link rel="alternate" type="text/html" href="http://kohlruebe.info/index.php?title=Understanding_5CLADBA:_An_Overview_For_Responsible_Research&amp;diff=39975"/>
		<updated>2026-05-18T06:59:54Z</updated>

		<summary type="html">&lt;p&gt;MariaKimbrell2: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of the Council of Europe on medico-legal autopsies. Elegans demonstrated the ability to form all of the in-vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in-vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup, physiological conditions (age, gender 4F ADB and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite.&amp;lt;br&amp;gt;Victim B also brought &amp;quot;something resembling a drug&amp;quot; (unrecognizable by Witness A) from his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco. The half-maximal effective concentration (EC50) of 4F-MDMB-BINACA is 5.69 nM (2.76–11.0 nM) on CB1, and 0.69 nM (0.30–1.56 nM) on CB2, in vitro half-life (t1/2) is 10.27 min . It is usually available as a powder, liquid (vapor fluid), or herbal plant mixtur&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f-adb.com/ 4F ADB] retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.&amp;lt;br&amp;gt;Data availabili&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Despite the relatively high % peak area ratio and detection in 16/20 urine samples, ester hydrolysis followed by monohydroxylation at the tert-leucine moiety (m/z 366, B8) metabolite was not reported among the 17 urine samples from the forensic psychiatric ward and prison in Haschimi et al.’s study&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali&lt;/div&gt;</summary>
		<author><name>MariaKimbrell2</name></author>
	</entry>
	<entry>
		<id>http://kohlruebe.info/index.php?title=Benutzer:MariaKimbrell2&amp;diff=39974</id>
		<title>Benutzer:MariaKimbrell2</title>
		<link rel="alternate" type="text/html" href="http://kohlruebe.info/index.php?title=Benutzer:MariaKimbrell2&amp;diff=39974"/>
		<updated>2026-05-18T06:59:41Z</updated>

		<summary type="html">&lt;p&gt;MariaKimbrell2: Die Seite wurde neu angelegt: „22 year old Account Coordinator Aurelie Ferraron, hailing from Saint-Hyacinthe enjoys watching movies like Nömadak TX and Snowboarding. Took a trip to Archaeological Site of Cyrene and drives a Ferrari 250 GT SWB &amp;quot;Competition&amp;quot; Berlinetta Speciale.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;my site - [https://cannabinoidsrc4f-adb.com/ 4F ADB]“&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;22 year old Account Coordinator Aurelie Ferraron, hailing from Saint-Hyacinthe enjoys watching movies like Nömadak TX and Snowboarding. Took a trip to Archaeological Site of Cyrene and drives a Ferrari 250 GT SWB &amp;quot;Competition&amp;quot; Berlinetta Speciale.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;my site - [https://cannabinoidsrc4f-adb.com/ 4F ADB]&lt;/div&gt;</summary>
		<author><name>MariaKimbrell2</name></author>
	</entry>
</feed>